EUPRAXIA PHARMACEUTICALS INC.
No enriched coverage for $EPRX in the last 7 days.
No SEC Form 4 filings for $EPRX in the last 30 days.
Eupraxia Pharmaceuticals to Host Virtual KOL Event to Discuss the Phase 1b/2a RESOLVE Study of EP-104GI for the Treatment of Eosinophilic Esophagitis ...
Data from Phase 1b/2a RESOLVE suggests EP-104GI has significant potential to improve the standard of care for patients with Eosinophilic Esophagitis ...
VICTORIA, British Columbia, April 24, 2025 ( GLOBE NEWSWIRE ) -- Eupraxia Pharmaceuticals Inc. ( "Eupraxia" or the "Company" ) EPRX EPRX, a clinical-stage biotechnology company leveraging its proprietary DiffuSphere™ technology designed to optimize drug delivery for applications with significant ...
